Scleroderma, Lupus and Dermatomyositis (2026 IMCU)

Learning Objectives:

• SSc Is a Multisystem Fibrotic Disease driven by the pathophysiologic triad of immune activation, vascular injury, and fibroblast activation — with ILD and PAH as the leading causes of mortality.
• Expanding Therapeutic Arsenal FDA-approved agents now include tocilizumab (IL-6 blockade), nintedanib (triple tyrosine kinase inhibitor), and nerandomilast (PDE4B inhibitor) — for Systemic Sclerosis
• Apply Myositis-Specific Antibody Profiles Correlate myositis-specific antibodies (Anti-TIF1γ, Anti-MDA-5, Anti-Jo-1, Anti-Mi-2) with their clinical phenotypes, prognostic implications, and malignancy associations to guide workup and management.